Craig Taylor
Co-Founder & General Partner @ Alloy Ventures
San Francisco Bay Area, United States
Craig Taylor is a Series B investor at Alloy Ventures in San Francisco Bay Area focused on Health Care and Biotechnology. Craig C. Taylor has been an active venture capitalist since 1977, and co-founded Alloy Ventures with John Shoch in 1996. At Alloy, he focuses on investments in laboratory instrumentation, diagnostics and cleantech, especially green-focused companies that sit at the intersection of biotech, nanotech and IT.Craig is a veteran venture capitalinvestor and expert in technology transfer from leading research institutions. Before co-founding Alloy Ventures, he worked at Asset Management Co., which he joined in 1977. Previously, Craig worked in the Office of Technology Licensing at Stanford University from 1975 to 1977. He is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford (1977).Craig serves on the board of directors of ForteBio, Labcyte, Optimedica, Zyomyx, and KFx Medical.Craig has led successful investments in, and served on the boards of, dozens of leading life science companies. He was a founding board member of Applied Biosystems, the pioneering biotechnology company founded in 1981 that was later became a division of Applera and was recently sold for $6.7 billion to Invitrogen Corp. He was also a founding board member of Adeza Biomedical, a woman's health company that completed a public offering on Nasdaq in 2004 and was later acquired by Cytec. He also served on the board of Lynx Therapeutics, a provider of genetic analysis tools for biological research that completed an IPO on Nasdaq in 2000, and later merged with Solex Ltd., before it was acquired by Illumina for $600 million 2006.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Craig Taylor invests in
Stages Craig Taylor invests in
Countries Craig Taylor invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
- Series E 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care.Since its founding,OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalysâ„¢ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011. | $35M / Series E / May 10, 2013 | ||
| OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care.Since its founding,OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalysâ„¢ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011. | $16M / Series C / Mar 26, 2008 | ||
| OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care.Since its founding,OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalysâ„¢ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011. | Series B / Apr 26, 2006 |
Co-Investors
About Alloy Ventures
Alloy Ventures is an early stage venture capital firm that invests in the areas of life sciences, information technology, and cleantech.
Alloy Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Craig Taylor
Co-Founder & General Partner
|
|||
Dave Pidwell
Venture Partner
|
|||
John Shoch
Co-Founder & General Partner
|
|||
Leighton Read
Venture Partner
|
|||
Leighton Read
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Craig Taylor invest in?
Craig Taylor invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Craig Taylor?
Public channels for Craig Taylor include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Craig Taylor last invest?
The most recent investment recorded for Craig Taylor closed in May 2013. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
